The Biotech Stock That Crashed, Then Pulled a Houdini
Capricor's Duchenne drug got crushed 9-3 at an FDA advisory committee, and its stock cratered to $4. Then the FDA agreed to review an amended filing, and everything changed overnight. The comeback story Wall Street didn't see coming.
Dead on Arrival? Not So Fast.
Imagine failing a final exam, then convincing the professor to let you submit extra credit. That's basically what Capricor Therapeutics just pulled off with the FDA.
The company's stock had been in free fall. Its Duchenne muscular dystrophy therapy, deramiocel, got hammered at an FDA advisory committee meeting, with panelists voting 9 to 3 against the drug's evidence of effectiveness. Shares were trading near $4, down from the mid-$20s earlier in the year. The obituaries were practically written.
Then, on August 14, Capricor dropped a bombshell: the FDA agreed to review an amended filing with new data. The stock ripped to $6.65 on trading volume of over 66 million shares. Wall Street analysts scrambled to rewrite their models. And suddenly, a drug that looked dead had a pulse again.
What Went Wrong at the Advisory Committee
To understand the comeback, you need to understand the crash. FDA advisory committees ("adcoms") are panels of outside experts who vote on whether a drug's data is convincing enough for approval. Their votes are non-binding, meaning the FDA can ignore them. But a lopsided 9-3 rejection is hard to shake off.
The panel's concerns boiled down to a few big problems. First, Capricor changed some of its key analyses after the trial ended. In clinical research, that's a red flag; it's like a student revising their hypothesis after they already know the answer. FDA staff flagged that the company altered how it measured both arm function and heart outcomes.
Second, the cardiac data was shaky. Some patients had missing data, and the average patient's heart function was actually normal at the start of the trial. That made it tough to prove the drug was improving hearts that weren't clearly damaged yet. Several panelists said they'd want a bigger, longer study before they could be convinced.
But here's the twist that got lost in the headlines: the committee only voted on a narrow question about heart-related evidence. When the discussion turned to upper limb function (basically, whether patients could use their arms better), the feedback was described as . The committee never actually voted on the broader picture.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
directionally supportive
The Clinical Data Isn't All Bad
Capricor's pivotal trial, called HOPE-3, did hit its primary endpoint. The study measured changes in upper limb function using a standardized scoring system, and deramiocel showed a statistically significant benefit over placebo, with a p-value of 0.03. For the non-statisticians: that means there's roughly a 3% chance the result was a fluke, which clears the conventional bar for significance.
The trial also showed meaningful secondary results. Heart fibrosis (scarring) was reduced with a p-value of 0.022. Patients with baseline heart problems saw their cardiac pumping function improve by 3.3 percentage points compared to placebo. And on a practical test measuring how well patients could eat independently, the drug slowed decline by about 83% versus placebo.
So the data wasn't a disaster. It was more like a movie that got mixed reviews: some critics loved the plot, others hated the ending, and the audience was split.
The Houdini Move: Amending the Filing
Capricor's plan is to submit a BLA amendment (a BLA is a Biologics License Application, essentially the formal request asking the FDA to approve a biologic drug). This amendment would include 24-month open-label extension data from HOPE-3, giving regulators a longer look at how patients fared over time.
The critical detail: the FDA said it's willing to review this amended package. That's not automatic. The agency could have told Capricor to go run a whole new trial. Instead, it left the door open, which analysts interpreted as a quietly encouraging signal.
The amendment would likely be treated as a "major amendment," pushing the review timeline back by roughly three months from the original August 22 PDUFA date (the FDA's deadline to make a decision). That delay sounds annoying, but compared to the alternative of starting over from scratch, it's a gift.
Analysts Changed Their Tune Overnight
The shift in Wall Street sentiment was dramatic. Cantor Fitzgerald upgraded Capricor from Neutral to Overweight and raised its price target from $3.50 all the way to $28. That's an 8x increase in their target price, which is the analyst equivalent of going from "maybe don't" to "back up the truck."
Oppenheimer reiterated its Outperform rating, calling the risk-reward setup attractive.
History Says Don't Count Them Out
Negative adcom votes feel like death sentences, but the historical record tells a different story. A 2022 study found that several drugs initially rejected by advisory committees were later approved. Dapagliflozin, flibanserin, lorcaserin, and cangrelor all followed the same arc: thumbs down from the panel, then eventual FDA approval after sponsors addressed the concerns or brought new data.
The FDA has actually shown a pattern of being more willing to approve after a negative vote than to reject after a positive one. The agency often doesn't even reconvene the advisory committee for the revised filing. It just reviews the updated package and makes its call.
That historical pattern is exactly what Capricor is banking on.
The Bigger Picture: A Crowded Race for Duchenne Patients
Duchenne muscular dystrophy remains one of biotech's most competitive therapeutic areas. Sarepta dominates the landscape with Elevidys (the only approved gene therapy for DMD) plus three exon-skipping drugs. Regenxbio is pushing its own gene therapy candidate toward a potential approval in the second half of 2027. Avidity Biosciences and Dyne Therapeutics are developing next-generation approaches that could reshape the field.
Capricor's therapy is a different beast entirely: deramiocel is a cell-based treatment, not a gene therapy or an exon-skipping drug. If approved, it would offer a mechanistically distinct option in a market that desperately needs more tools.
But "if" is doing a lot of heavy lifting in that sentence. The amended filing still needs to convince the FDA that the totality of data, including those new 24-month results, is strong enough to warrant approval. The cardiac questions haven't disappeared; they've just been given a chance at a retest.
For Duchenne families watching this saga unfold, the stakes couldn't be higher. This is a progressive, life-shortening disease with limited treatment options. Every potential therapy that stays alive in the pipeline represents hope.
Capricor's stock might have pulled a Houdini. Whether the drug itself can escape the regulatory straitjacket is the question that matters most.
Clinical & Regulatory
4 min read
When the FDA Commissioner Tries to Kill a Drug Himself
Reports claim FDA Commissioner Marty Makary personally tried to block KalVista's rare disease drug, an almost unprecedented intervention that raises uncomfortable questions about political influence at the agency. The drug got approved anyway, but the fallout is just beginning.
